PROBLEM TO BE SOLVED: To provide a novel immunotherapy against several tumors including gastrointestinal and gastric cancer.SOLUTION: According to the present invention, there are provided peptides, nucleic acids, and cells for use in immunotherapeutic methods, particularly use in the immunotherapy of cancer. According to the present invention, there are also provided tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. There are also provided 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. According to the present invention, the peptide is capable of inducing a T cells cross-reaction, and is preferably not a full-length polypeptide. The peptide has an overall length of from 8 to 100 amino acids, from 8 to 30 amino acids, or from 8 to 14 amino acids.SELECTED DRAWING: None【課題】消化管癌および胃癌を含む数種の腫瘍に対する新規免疫療法の提供。【解決手段】免疫療法で用いられるペプチド、核酸および細胞に関し、特にがんの免疫療法に使用する。さらに、腫瘍関連障害性T細胞（CTL）のペプチドエピトープ単独について、あるいは抗腫瘍免疫応答を刺激するワクチン組成物の薬剤有効成分とて働く他の腫瘍関連ペプチドとこれらエピトープとの組み合わせ。抗腫瘍免疫応答を誘発するワクチン組成物で使用され、ヒト腫瘍細胞のHLAクラスI分子に由来する95個の新規ペプチド配列と変異体。前記ペプチドはＴ細胞交差反応を誘導するものであって、好まくは全長ポリペプチドではなく、８～１００アノ酸長、８～３０アミノ酸長又は８～１４アミノ酸長である、ペプチド。【選択図】なし
